Literature DB >> 7931357

Chronic morphine administration increases beta-adrenergic receptor kinase (beta ARK) levels in the rat locus coeruleus.

R Z Terwilliger1, J Ortiz, X Guitart, E J Nestler.   

Abstract

Based on the established role of beta-adrenergic receptor kinase (beta ARK) and beta-arrestin in the desensitization of several G protein-coupled receptors, we investigated the effect of chronic morphine administration on beta ARK and beta-arrestin levels in selected brain areas. Levels of beta ARK were measured by blot immunolabeling analysis using antibodies specific for two known forms of beta ARK, i.e., beta ARK1 and beta ARK2. It was found that chronic morphine treatment produced an approximately 35% increase in levels of beta ARK1 immunoreactivity in the locus coeruleus, but not in several other brain regions studied. In contrast, chronic morphine treatment failed to alter levels of beta ARK2 immunoreactivity in any of the brain regions studied. Levels of beta-arrestin immunoreactivity, measured using an antiserum that recognizes two major forms of this protein in brain, were also found to increase (by approximately 20%) in the locus coeruleus. It is proposed that chronic morphine regulation of beta ARK1 and beta-arrestin levels may contribute to opioid-receptor tolerance that is known to occur in this brain region.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7931357     DOI: 10.1046/j.1471-4159.1994.63051983.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  18 in total

1.  The enigma of morphine tolerance: recent insights.

Authors:  S B Ray; S Wadhwa
Journal:  J Biosci       Date:  2001-12       Impact factor: 1.826

2.  Chronic morphine treatment reduces recovery from opioid desensitization.

Authors:  Vu C Dang; John T Williams
Journal:  J Neurosci       Date:  2004-09-01       Impact factor: 6.167

Review 3.  G protein-coupled receptor kinase/beta-arrestin systems and drugs of abuse: psychostimulant and opiate studies in knockout mice.

Authors:  Laura M Bohn; Raul R Gainetdinov; Marc G Caron
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

Review 4.  Opioid receptor trafficking and signaling: what happens after opioid receptor activation?

Authors:  Jia-Ming Bian; Ning Wu; Rui-Bin Su; Jin Li
Journal:  Cell Mol Neurobiol       Date:  2011-09-25       Impact factor: 5.046

Review 5.  New perspectives regarding β(2) -adrenoceptor ligands in the treatment of asthma.

Authors:  J K L Walker; R B Penn; N A Hanania; B F Dickey; R A Bond
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

Review 6.  Mu opioid receptor regulation and opiate responsiveness.

Authors:  Kirsten M Raehal; Laura M Bohn
Journal:  AAPS J       Date:  2005-10-19       Impact factor: 4.009

Review 7.  Once and future signaling: G protein-coupled receptor kinase control of neuronal sensitivity.

Authors:  Richard T Premont
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

8.  Prolonged Morphine Treatment Alters Expression and Plasma Membrane Distribution of β-Adrenergic Receptors and Some Other Components of Their Signaling System in Rat Cerebral Cortex.

Authors:  Lucie Hejnova; Jitka Skrabalova; Jiri Novotny
Journal:  J Mol Neurosci       Date:  2017-10-28       Impact factor: 3.444

9.  Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness.

Authors:  J Zhang; S S Ferguson; L S Barak; S R Bodduluri; S A Laporte; P Y Law; M G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

Review 10.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.